A novel cancer immunotherapy utilizing autologous tumour tissue
Authors:
- 6 May 2020
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 115 (6) , 525-535
Abstract
Background: With the recent interest in personalized medicine for cancer patients and immune therapy, the field of cancer vaccines has been resurrected. Previous autologous, whole cell tumour vaccine trials have not produced convincing results due, in part to poor patient selection and inactivation methos that are harsh on the cells. These methods can alter protein structure and antigenic profiles making vaccine candidates ineffective in stimulating immune response to autochthonous tumour cells.Materials and methods: We investigated a novel method for inactivating tumour cells that uses UVA/UVB light and riboflavin (vitamin B2) (RF + UV). RF + UV inactivates the tumour cells’ ability to replicate, yet preserves tumour cell integrity and antigenicity.Results: Our results demonstrate that proteins are preserved on the surface of RF + UV‐inactivated tumour cells and that they are immunogenic via induction of dendritic cell maturation, increase in IFNγ production and generation of tumour cell‐specific IgG. Moreover, when formulated with an adjuvant (‘Innocell vaccine’) and tested in different murine tumour primary and metastatic disease models, decreased tumour growth, decreased metastatic disease and prolonged survival were observed. In addition, immune cells obtained from tumour tissue following vaccination had decreased exhausted and regulatory T cells, suggesting that activation of intra‐tumoural T cells may be playing a role leading to reduced tumour growth.Conclusions: These data suggest that the RF + UV inactivation of tumour cells may provide an efficacious method for generating autologous whole tumour cell vaccines for use in cancer patients.Keywords
Funding Information
- Colorado Office of Economic Development and International Trade (5363043)
- PhotonPharma, Inc.
This publication has 28 references indexed in Scilit:
- Optimized dosing of a CCR2 antagonist for amplification of vaccine immunityInternational Immunopharmacology, 2013
- Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma ModelThe Journal of Immunology, 2013
- Suppression of Vaccine Immunity by Inflammatory MonocytesThe Journal of Immunology, 2012
- Naturally occurring regulatory T cells: markers, mechanisms, and manipulationThe FASEB Journal, 2012
- Death by protein damage in irradiated cellsDNA Repair, 2012
- Polymerase chain reaction–based species verification and microsatellite analysis for canine cell line validationJournal of Veterinary Diagnostic Investigation, 2011
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and lightTransfusion, 2004
- The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.Proceedings of the National Academy of Sciences, 1996
- Effects of ultraviolet radiation on mammalian cells I. Induction of chromosome aberrationsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1965